Flualprazolam is a novel depressant substance of the benzodiazepine class. Flualprazolam is chemically related to alprazolam (Xanax), differing by the addition of a fluorine atom, and is reported to produce similar psychoactive effects.

Flualprazolam appears to have first become available for sale on the online research chemical market in 2017. It currently remains unscheduled.

Users should note that the sudden discontinuation of benzodiazepines can be dangerous or even life-threatening for individuals for heavy or long-term users. As a result, individuals who are physically dependent on this substance are advised to taper their dose by gradually lowering the amount taken each day over a prolonged period instead of stopping use abruptly.

It is strongly advised to use harm reduction practices when using this substance.

Flualprazolam is a benzodiazepine derivative which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in Sweden in 2018. It can be described as the 2′-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.